Nucleic Acids in Innate Immunity

Nucleic Acids in Innate Immunity
Author: Ken J Ishii
Publisher: CRC Press
Total Pages: 304
Release: 2019-08-30
Genre:
ISBN: 9780367387297

Until recently, innate immunity was regarded as a relatively nonspecific system designed to engulf and destroy pathogens. However, new studies show that the innate immune system is highly developed in its ability to discriminate between self and foreign entities. Understanding this mechanism can lead to therapeutic strategies based on manipulation of this previously unexploited branch of the immune system. Drawing on the research of leading experts, Nucleic Acids in Innate Immunity provides insight in this new area of immunology. The book begins by explaining the roles of nucleic acids in immunity, describing the mechanism of discrimination based on pattern-recognition receptors (PRRs), including Toll-like receptors (TLRs), Nod-like receptors (NLR), and RIG-I-like receptors (RLR). Chapters discuss how these PRRs recognize and respond to pathogen-associated molecular patterns (PAMPs) by activating specific signaling pathways. The second section focuses on the therapeutic applications of immunomodulatory DNA by manipulating released pathogenic nucleic acids as immune system stimulants. The book introduces novel therapeutics developed to prevent or treat infectious diseases, allergic disorders, and cancer, as well as clearing unnecessary or abnormal host molecules. The final section addresses how the immune system discriminates self and non-self RNA. Recent findings that host (self) nucleic acids are not inert in the immune system beg the question of exactly what elements within DNA or RNA are recognized by the innate immune system. Contributions review recent advances to understand innate immune recognition of nucleic acids and describe the resulting immune modulation. Providing a comprehensive review of nucleic acid recognition and regulation by the innate immune system, this seminal work reveals new directions for future research in immune modulation.

Delivery Technologies for Biopharmaceuticals

Delivery Technologies for Biopharmaceuticals
Author: Lene Jorgensen
Publisher: John Wiley & Sons
Total Pages: 442
Release: 2009-10-23
Genre: Science
ISBN: 0470688408

Advances in biotechnology have provided scientists with an increasing number of biopharmaceuticals such as novel peptide and protein drugs as well as nucleic acid based drugs for gene therapy. However, successful delivery of these biopharmaceuticals is a major challenge because their molecular properties lead to poor physical and chemical stability in the body and limited membrane permeability. Therefore researchers are developing a range of new delivery technologies and materials to enable these new drugs to be delivered intact to their target sites. Delivery Technologies for Biopharmaceuticals describes strategies to overcome the main barriers for successful delivery of therapeutic peptides, proteins, and nucleic acid-based drugs or vaccines related to the site of administration and the target site. Many of the approaches described are reported in formulations in current clinical trials as well as in marketed products. Contents include: challenges in delivery of biopharmaceuticals novel formulation approaches for peptide and protein injectables non-viral chemical vectors and viral technology for delivery of nucleic acid based drugs immune response, adjuvants and delivery systems for vaccines several examples of delivery systems for different biopharmaceuticals a critical assessment of delivery technologies for biopharmaceuticals Delivery Technologies for Biopharmaceuticals is an essential single-volume introduction to the technologies used by researchers to ensure efficient delivery of this exciting new class of drugs. It will be of value to researchers and students working in drug delivery, formulation, biopharmaceuticals, medicinal chemistry, and new materials development.

Nucleic Acid Sensing and Immunity, Part A

Nucleic Acid Sensing and Immunity, Part A
Author:
Publisher: Academic Press
Total Pages: 269
Release: 2019-02-22
Genre: Science
ISBN: 0128159804

Nucleic Acid Sensing and Immunity - PART A, Volume 344, provides a comprehensive overview of the nucleic acid machinery, from plants to mammalians, as well as their regulation. Specific chapters in this updated release include Molecular bases of discrimination between self from non-self nucleic acids, Intracellular RNA sensing in mammalian cells, Nuclear DNA damage and nucleic acid sensing, Negative regulation of nucleic acid sensing, Dendritic cell responses to exogenous nucleic acids, Activating the nucleic acid-sensing machinery for anticancer immunity, and Nucleic acid sensing and inflammasomes, amongst other topics. Provides an accurate, state-of-the-art resource on RNA sensing Includes the work of a well-known tumor immunologist Links intestinal host defense and viral nucleic acid sensing Presents a chapter on the negative regulation of DNA sensing, a timely topic

Therapeutic Oligonucleotides

Therapeutic Oligonucleotides
Author: Jens Kurreck
Publisher: Royal Society of Chemistry
Total Pages: 362
Release: 2008
Genre: Medical
ISBN: 0854041168

This book provides a compelling overall update on current status of RNA interference

Nucleic Acids as Gene Anticancer Drug Delivery Therapy

Nucleic Acids as Gene Anticancer Drug Delivery Therapy
Author: Loutfy H. Madkour
Publisher: Academic Press
Total Pages: 650
Release: 2019-08-27
Genre: Business & Economics
ISBN: 0128197781

Nucleic Acids as Gene Anticancer Drug Delivery Therapy highlights the most recent developments in cancer treatment using nucleic acids, nanoparticles and polymer nanoparticles for genomic nanocarriers as drug delivery, including promising opportunities for targeted and combination therapy. The development of a wide spectrum of nanoscale technologies is beginning to change the scientific landscape in terms of disease diagnosis, treatment, and prevention. This book presents the use of nanotechnology for medical applications, focusing on its use for anticancer drug delivery. Various intelligent drug delivery systems such as inorganic nanoparticles and polymer-based drug delivery are discussed. The use of smart drug delivery systems seems to be a promising approach for developing intelligent therapeutic systems for cancer immunotherapies and is discussed in detail along with nucleic acid-targeted drug delivery combination therapy for cancer. Nucleic Acids as Gene Anticancer Drug Delivery Therapy will be a useful reference for pharmaceutical scientists, pharmacologiests, and those involved in nanotechnology and cancer research. Discusses intelligent drug delivery systems such as inorganic nanoparticles and polymer-based drug delivery Contains a comprehensive comparison of various delivery systems, listing their advantages and limitations Presents combination therapy as a new hope for enhancing current gene-based treatment efficacy

RNA Nanotechnology

RNA Nanotechnology
Author: Bin Wang
Publisher: CRC Press
Total Pages: 468
Release: 2014-04-02
Genre: Medical
ISBN: 9814411647

In the past few decades there has been incredible growth in "bionano"-related research, which has been accompanied by numerous publications in this field. Although various compilations address topics related to deoxyribonucleic acid (DNA) and protein, there are few books that focus on determining the structure of ribonucleic acid (RNA) and using RNA as building blocks to construct nanoarchitectures for biomedical and healthcare applications. RNA Nanotechnology is a comprehensive volume that details both the traditional approaches and the latest developments in the field of RNA-related technology. This book targets a wide audience: a broad introduction provides a solid academic background for students, researchers, and scientists who are unfamiliar with the subject, while the in-depth descriptions and discussions are useful for advanced professionals. The book opens with reviews on the basic aspects of RNA biology, computational approaches for predicting RNA structures, and traditional and emerging experimental approaches for probing RNA structures. This section is followed by explorations of the latest research and discoveries in RNA nanotechnology, including the design and construction of RNA-based nanostructures. The final segment of the book includes descriptions and discussions of the potential biological and therapeutic applications of small RNA molecules, such as small/short interfering RNAs (siRNAs), microRNAs (miRNAs), RNA aptamers, and ribozymes.

Toll-Like Receptors (TLRs) and Innate Immunity

Toll-Like Receptors (TLRs) and Innate Immunity
Author: Stefan Bauer
Publisher: Springer Science & Business Media
Total Pages: 243
Release: 2007-12-11
Genre: Medical
ISBN: 3540721673

Overall recent research on TLRs has led to tremendous increase in our understanding of early steps in pathogen recognition and will presumably lead to potent TLR targeting therapeutics in the future. This book reviews and highlights our recent understanding on the function and ligands of TLRs as well as their role in autoimmunity, dendritic cell activation and target structures for therapeutic intervention.

Simultaneous, Single-carrier Delivery of Antigens and Immune-modulatory Molecules to Dendritic Cells

Simultaneous, Single-carrier Delivery of Antigens and Immune-modulatory Molecules to Dendritic Cells
Author: Eileen Regina Dawson
Publisher:
Total Pages: 304
Release: 2013
Genre:
ISBN:

Immunotherapy as a means for cancer treatment has been investigated for over a century. While studies have been completed using different immunological strategies, development of a clinical therapeutic cancer vaccine has proven elusive. Recently, success has been seen with prophylactic vaccines for cancers with known viral origins (Gardasil® and Cervarix for Human Papiloma Virus). However, such strategies do not address the challenge in generating effective immune response against other tumor antigens, most of which are weakly immunogenic self-antigens. Tolerance to these self-antigens could ultimately limit the patient's ability to mount an effective anti-tumor immune response. The US Food and Drug Administration recently approved the first DC cell-based cancer vaccine, Provenge®, for use in prostate cancer. This vaccine requires cell isolations from the patient as well as in vitro DC modifications, which ultimately leads to high cost as well as multiple procedures. However, results indicate that, on average, patients live only four months longer than those receiving a placebo. While this work remains important, and offers proof that priming DCs can improve the lifespan of a patient, it ultimately does not offer a long-term cure. Direct and highly efficient in vivo delivery of antigens to DCs could overcome the challenges associated with ex vivo DC manipulation and may offer a more scalable method for generating anti-tumor immunity. This research focuses on the development of novel formulations that allow simultaneous delivery of protein/peptide-based tumor antigens and immune-modulatory nucleic acids (siRNA and immune stimulatory CpG) to the same dendritic cells (DCs) in-vivo. Such formulations allow a synthetic immune-priming center to be created at the site of immunization and simultaneously deliver the tumor antigen to DCs and modulate their immune response through IL-10 silencing. Our hypothesis is that using such a DC-targeted dual delivery system we will be able to illicit strong T helper 1 (TH1) and Cytotxic T Lymphocyte (CTL) response in vivo against a wide array of tumor antigens. This can become a platform technology where the biomolecules (antigen and immunomodulatory agents) can be easily varied based on particular cancers.

Oligonucleotide-Based Drugs and Therapeutics

Oligonucleotide-Based Drugs and Therapeutics
Author: Nicolay Ferrari
Publisher: John Wiley & Sons
Total Pages: 576
Release: 2018-07-31
Genre: Medical
ISBN: 1118537335

A comprehensive review of contemporary antisense oligonucleotides drugs and therapeutic principles, methods, applications, and research Oligonucleotide-based drugs, in particular antisense oligonucleotides, are part of a growing number of pharmaceutical and biotech programs progressing to treat a wide range of indications including cancer, cardiovascular, neurodegenerative, neuromuscular, and respiratory diseases, as well as other severe and rare diseases. Reviewing fundamentals and offering guidelines for drug discovery and development, this book is a practical guide covering all key aspects of this increasingly popular area of pharmacology and biotech and pharma research, from the basic science behind antisense oligonucleotides chemistry, toxicology, manufacturing, to safety assessments, the design of therapeutic protocols, to clinical experience. Antisense oligonucleotides are single strands of DNA or RNA that are complementary to a chosen sequence. While the idea of antisense oligonucleotides to target single genes dates back to the 1970's, most advances have taken place in recent years. The increasing number of antisense oligonucleotide programs in clinical development is a testament to the progress and understanding of pharmacologic, pharmacokinetic, and toxicologic properties as well as improvement in the delivery of oligonucleotides. This valuable book reviews the fundamentals of oligonucleotides, with a focus on antisense oligonucleotide drugs, and reports on the latest research underway worldwide. • Helps readers understand antisense molecules and their targets, biochemistry, and toxicity mechanisms, roles in disease, and applications for safety and therapeutics • Examines the principles, practices, and tools for scientists in both pre-clinical and clinical settings and how to apply them to antisense oligonucleotides • Provides guidelines for scientists in drug design and discovery to help improve efficiency, assessment, and the success of drug candidates • Includes interdisciplinary perspectives, from academia, industry, regulatory and from the fields of pharmacology, toxicology, biology, and medicinal chemistry Oligonucleotide-Based Drugs and Therapeutics belongs on the reference shelves of chemists, pharmaceutical scientists, chemical biologists, toxicologists and other scientists working in the pharmaceutical and biotechnology industries. It will also be a valuable resource for regulatory specialists and safety assessment professionals and an important reference for academic researchers and post-graduates interested in therapeutics, antisense therapy, and oligonucleotides.